索拉非尼联合肝动脉化疗栓塞术治疗中晚期肝细胞癌疗效观察*

doi:10.3969/j.issn.1672-5069.2015.01.015

实用肝脏病杂志 ›› 2015, Vol. 18 ›› Issue (1): 59-62.doi: 10.3969/j.issn.1672-5069.2015.01.015

索拉非尼联合肝动脉化疗栓塞术治疗中晚期肝细胞癌疗效观察^*

周学士, 任雷, 彭蕾, 叶阳群, 朱晓黎, 冯婷婷, 赵卫峰

214000 江苏省无锡市第五人民医院肝科七病区（周学士）; 苏州大学附属第一医院感染病科（赵卫峰,任雷,彭蕾,朱晓黎,冯婷婷）; 无锡市惠山区长安街道卫生服务中心（叶阳群）

收稿日期:2014-05-26 出版日期:2015-12-17 发布日期:2015-12-17
通讯作者: 赵卫峰,E-mail：zhaoweifeng@suda.edu.cn E-mail:moka861220@163.com
作者简介:周学士,男,28岁,医学硕士。主要从事感染病临床诊治工作。E-mail：moka861220@163.com
基金资助:
江苏省自然科学基金资助项目（编号BK20130271）

Efficacy of transcatheter arterial chemoembolization combined with sorafenib in treatment of patients with advanced hepatocellular carcinoma

Zhou Xueshi, Ren Lei, Peng Lei, et al

Department of Hepatology, Fifth People's Hospital,Wuxi 214005,Jiangsu Province,China

Received:2014-05-26 Online:2015-12-17 Published:2015-12-17

摘要/Abstract

摘要： 目的观察经导管肝动脉化疗栓塞术（TACE）与靶向治疗药相结合治疗中晚期肝细胞癌的疗效和安全性。方法 2008年1月至2012年12月我院收治的中晚期肝细胞癌患者60例,均采用TACE治疗,其中37例术后口服索拉非尼（400 mg,2次/d）,根据不良反应调整用量,定期复查腹部CT。根据mRECIST标准进行疗效评价,观察患者的肿瘤进展时间和总生存期,并记录索拉非尼不良反应和TACE前后的肝功能变化。结果 37例应用TACE联合索拉非尼治疗患者的中位生存期为（13±0.98）m,显著长于23例单纯TACE治疗组[（7.3±1.20）m,P=0.001],肿瘤进展时间为（7.5±1.21）m,显著长于单纯TACE治疗组[（5±0.62）m,P=0.001];在随访结束时,联合治疗组疾病控制率为48.6%,显著高于单纯TACE组的17.4%（P<0.01）;多因素分析显示有无联合应用索拉非尼、有无门脉癌栓、是否抗病毒治疗是显著影响生存时间的风险因素;索拉非尼治疗主要的相关不良反应为手足皮肤反应。结论 TACE联合索拉非尼治疗可延长中晚期肝细胞癌患者的疾病进展时间及总生存期,安全性好。

关键词: 肝细胞癌, 肝动脉化疗栓塞术, 索拉非尼, 预后

Abstract: Objective To observe the efficacy and safety of transcatheter arterial chemoembolization （TACE） combined with targeted therapy for advanced hepatocellular carcinoma. Methods From Jan. 2008,to Dec. 2012,60 cases of advanced hepatocellular carcinoma received TACE,among them,37 cases were treated with sorafenib after TACE,at a dose of 400 mg,twice a day（the dosage was adjusted according to the side effect）. Abdominal CT scans were regularly performed and treatment efficacy was evaluated according to the modified RECIST. The side effect of sorafenib was recorded,so was the liver function before and after TACE. Results In 37 patients received combined treatment（TACE plus sorafenib） and 23 patients received TACE alone,the median overall survival time were （13±0.98） months and （5±0.62） months,respectively （P=0.001）,the time to progression were （7.5±1.21） months and （5±0.62） months,respectively （P=0.001）,and at the end of followed-up,the disease control rate were 48.6% and 17.4% in the two groups,respectively（P<0.01）;The multivariate analysis showed that the risk factors for death were without combination of sorafenib and antiviral therapy,and the presence of portal vein tumor thrombus. The main side effect of sorafenib was hand-foot skin reaction. Conclusion TACE combined with sorafenib has prolonged time to disease progression and overall survival time in patients with advanced hepatocellular carcinoma with relatively good safety.

Key words: Hepatocellular carcinoma, Transcatheter arterial chemoembolization, Sorafenib, Prognosis

周学士, 任雷, 彭蕾, 叶阳群, 朱晓黎, 冯婷婷, 赵卫峰. 索拉非尼联合肝动脉化疗栓塞术治疗中晚期肝细胞癌疗效观察^*[J]. 实用肝脏病杂志, 2015, 18(1): 59-62.

Zhou Xueshi, Ren Lei, Peng Lei, et al. Efficacy of transcatheter arterial chemoembolization combined with sorafenib in treatment of patients with advanced hepatocellular carcinoma[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(1): 59-62.

参考文献

[1] Marelli L,Stigliano R,Triantos C,et al. Transarterial therapy for hepatocellular carcinoma:which technique is more effective A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol,2007,30（1）:6-25.
[2] Li X,Feng G S,Zheng C S,et al. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol,2004,10（19）:2878-2882.
[3] Poon R T,Lau C,Yu W C,et al. High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma:a prospective study. Oncol Rep,2004,11（5）:1077-1084.
[4] Sergio A,Cristofori C,Cardin R,et al. Transcatheter arterial chemoembolization（TACE） in hepatocellular carcinoma （HCC）:the role of angiogenesis and invasiveness. Am J Gastroenterol,2008,103（4）:914-921.
[5] Shim J H,Park J W,Kim J H,et al. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci,2008,99（10）:2037-2044.
[6] Liu L,Cao Y,Chen C,et al. Sorafenib blocks the RAF/MEK/ERK pathway,inhibits tumor angiogenesis,and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res,2006,66（24）:11851-11858.
[7] Wilhelm S M,Carter C,Tang L,et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res,2004,64（19）:7099-7109.
[8] Llovet J M,Burroughs A,Bruix J. Hepatocellular carcinoma. Lancet,2003,362（9399）:1907-1917.
[9] Lencioni R,Llovet J M. Modified RECIST （mRECIST） assessment for hepatocellular carcinoma.Semin Liver Dis,2010,30（1）:52-60.
[10] Kamada K,Nakanishi T,Kitamoto M,et al. Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma:comparison of cisplatin lipiodol suspension and doxorubicin hydrochloride emulsion. J Vasc Interv Radiol,2001,12（7）:847-854.
[11] Wang B,Xu H,Gao Z Q,et al. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol,2008,49（5）:523-529.
[12] Cheng A L,Kang Y K,Chen Z,et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phase III randomised,double-blind, placebo-controlled trial. Lancet Oncol,2009,10（1）:25-34.
[13] Roayaie S,Obeidat K,Sposito C,et al. Resection of hepatocellular cancer </=2 cm:results from two Western centers. Hepatology,2013,57（4）:1426-1435.
[14] Cabrera R,Pannu D S,Caridi J,et al. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. Aliment Pharmacol Ther,2011,34（2）:205-213.
[15] Cheng A L, Kang Y K,Chen Z,et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phase III randomised,double-blind, placebo-controlled trial. Lancet Oncol,2009,10（1）:25-34.
[16] Hsu C,Po-Ching-Liang,Morita S,et al. Perspectives on the design of clinical trials combining transarterial chemoembolization and molecular targeted therapy. Liver Cancer,2012,1（3-4）:168-176.
[17] Hollebecque A,Cattan S,Romano O,et al. Safety and efficacy of sorafenib in hepatocellular carcinoma:the impact of the Child-Pugh score. Aliment Pharmacol Ther,2011,34（10）:1193-1201.
[18] Jang J W,Kwon J H,You C R,et al. Risk of HBV reactivation according to viral status and treatment intensity in patients with hepatocellular carcinoma. Antivir Ther,2011,16（7）:969-977.
[19] Miao R Y,Zhao H T,Yang H Y,et al. Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma:a meta-analysis. World J Gastroenterol,2010,16（23）:2931-2942.
[20] Toyoda H,Kumada T,Tada T,et al. Transarterial chemoembolization for hepatitis B virus-associated hepatocellular carcinoma: improved survival after concomitant treatment with nucleoside analogues. J Vasc Interv Radiol,2012,23（3）:317-322.

索拉非尼联合肝动脉化疗栓塞术治疗中晚期肝细胞癌疗效观察^*

Efficacy of transcatheter arterial chemoembolization combined with sorafenib in treatment of patients with advanced hepatocellular carcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	曹策, 郁义星, 王贝贝, 赵卫峰. 增强磁共振成像联合血清甲胎蛋白和脱-γ-羧基凝血酶原诊断肝细胞癌临床价值探讨[J]. 实用肝脏病杂志, 2019, 22(6): 896-899.
[2]	朱玉成, 闫家微, 孙景坤, 张秋月. 慢加急性肝衰竭患者血清二胺氧化酶水平及其临床意义探讨*[J]. 实用肝脏病杂志, 2019, 22(5): 672-675.
[3]	朱俊, 丁莹, 王世清, 张野, 刘野, 刘泽刚. 围手术期应用乌司他丁治疗对肝细胞癌患者肝切除术后外周血Th22细胞百分比和血浆白细胞介素-22的影响*[J]. 实用肝脏病杂志, 2019, 22(5): 720-723.
[4]	王刚, 赵洪波, 朱亚玲, 蒋保三, 张越美, 刁勇. 基于数据库分析肝细胞癌细胞XPO5基因水平变化及其临床意义*[J]. 实用肝脏病杂志, 2019, 22(5): 724-727.
[5]	庄太平, 尹杨艳, 谢蔓芳, 冯乃超, 陈彩华. 人巨细胞病毒感染与肝炎综合征婴儿临床特点比较^*[J]. 实用肝脏病杂志, 2019, 22(4): 514-517.
[6]	彭思璐, 刘冰, 孙宏, 林剑, 潘志颖, 邓存良. HBV相关慢加急性肝衰竭患者预后及其影响因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 545-548.
[7]	戴青云, 王润东, 荚卫东. 术前预后营养指数评估肝细胞癌患者肝切除术后早期肿瘤复发价值探讨^*[J]. 实用肝脏病杂志, 2019, 22(4): 561-564.
[8]	杨富存, 尚怀学, 盖永浩. 钆塞酸二钠增强磁共振扫描诊断肝脏局灶性病变研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 577-580.
[9]	彭新健, 肖玉辉, 许斯鼎, 石荣跃, 王耀政, 王瑜琳. 放射性肝损伤患者肝脏磁共振扩散加权成像表现特征分析[J]. 实用肝脏病杂志, 2019, 22(3): 373-376.
[10]	乔志忠. 超声造影定量分析鉴别肝脏局灶性结节性增生与原发性肝癌初步探讨[J]. 实用肝脏病杂志, 2019, 22(3): 421-424.
[11]	朱光曦（综述）, 文良志, 陈东风（审校）. 非酒精性脂肪性肝病相关肝细胞癌发病机制研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 453-456.
[12]	高朋彬,赵晓彦,秦浩,吴凤影,钟海振,王琳,贾慧娜,李树娟. 戊型肝炎肝衰竭死亡原因分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 220-223.
[13]	王虎明,樊东升,徐杰,刘险峰,周宁,丽敏,包娜娜. 肝细胞癌患者癌组织miRNA-30c水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(2): 248-251.
[14]	幸奠奎,程婧. ¹⁸F-FDG PET/CT检查指标预测肝细胞癌微血管侵犯临床价值研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 252-254.
[15]	王秀清,马艳君,詹晋莉. 肝动脉化疗栓塞术联合超声引导下微波消融术治疗特殊部位原发性肝癌患者疗效及安全性分析 ^*[J]. 实用肝脏病杂志, 2019, 22(2): 260-263.